ArticleLa Radiologia medica2026
High-dose-rate vaginal brachytherapy for treatment of recurrent high-grade vaginal intraepithelial neoplasia.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-dose-rate vaginal brachytherapy for treatment of recurrent high-grade vaginal intraepithelial neoplasia.La Radiologia medica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHigh-grade vaginal intraepithelial neoplasia (HG VaIN) is a rare preinvasive lesion characterized by a high risk of recurrence. Management strategies encompass both surgical excision, ablative procedures, and topical treatments. Brachytherapy provides a less invasive option, particularly for recurrent HG VaIN cases where other therapies have been unsuccessful or are not feasible. The present study assessed effectiveness and safety of brachytherapy in treating HG VaIN, with a focus on long-term outcomes, including local disease control, progression to invasive carcinoma, and treatment-associated adverse effects. MATERIAL AND
methodsA single-center retrospective analysis was performed on 31 patients with histologically proven HG VaIN who underwent brachytherapy at St. Anna University Hospital in Turin, Italy, from 1997 to 2024. High-dose-rate vaginal brachytherapy (HDR-VBT) was delivered, with dosage and fractionation schedules customized based on the characteristics of the lesions and individual patient factors.
resultsThe median age of the patients was 65 years, with 87.1% having a history of hysterectomy and 96.78% being postmenopausal. All patients had undergone multiple prior treatments (average of 3.7). Total radiation doses varied between 30 and 50 Gy, delivered across 5-10 sessions. Following a median follow-up period of 46.9 months, the local control rate at both 5-10 years was 96.8%, with no cases progressing to invasive carcinoma. Adverse effects were generally mild, with only one grade 3 event.
conclusionHDR-VBT provides excellent local disease control with low toxicity in patients with HG VaIN who have received prior treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.